Cefiderocol

ABSTRACT

Cefiderocol is a new siderophore cephalosporin with potent in vitro activity against gram-negative bacilli includingEnterobacterales that produce all kinds of carbapenemases andnon-fermenting Gram-negative with difficult-to-treat resistance. As a β-lactam, its efficacy is optimized in extended-perfusion and requires dose adjustment in renal dysfunction andhyperclearance. Its efficacy has been validated in three clinical trials, one of them in the treatment of hospital-acquiredpneumonia and ventilator-associated pneumonia. The clinicaltrial aimed at difficult-to-treat gram-negatives achieved theclinical and microbiological target, but the increase in mortalityobserved in the cefiderocol arm makes it necessary to demonstrate efficacy in real clinical practice. Cefiderocol is a goodoption among the new β-lactams for the treatment of pneumonia caused by Gram-negative bacilli carbapenem-resistant (AU)